Okinawa Buys Three Genome Analyzers To Boost Biopharma Research
This article was originally published in PharmAsia News
With financial support from the prefectural government, the Okinawa Health Biotechnology Research and Development Center has invested ¥0.29 billion and purchased three genome analyzers in an effort to speed up genetic analysis and boost research efficiency. A single facility with three such high-speed systems is a rarity and is the largest of its size in Japan. The move is aimed to improve biopharma research in Okinawa and provide a preferred research destination for pharmaceutical companies. Okinawa is known for its unique subtropical location and the population with the highest longevity in Japan. The Prefecture has actively promoted biopharma research activities to become a nationwide leader. According to local economic authorities, two leading Asian biopharma research areas, in Singapore and Beijing, have been actively investing in genome analyzers to accelerate research activities; Okinawa hopes to be competitive in Asia as well.(Click here for more-Japanese language
You may also be interested in...
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.